PPARG and type 2 diabetes mellitus: Synthetic PPARγ agonists (thiazolidinediones), such as rosiglitazone (ROSI), pioglitazone, and troglitazone, have been used for many years in patients with type 2 diabetes (T2DM) to improve insulin resistance and ameliorate hyperglycemia [3].